Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

103.81 -1.42 (-1.35%)

Streaming Delayed Price Updated: 1:45 PM EDT, Sep 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King ↗

September 08, 2026

Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes.

Via The Motley Fool

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) ↗

September 05, 2026

Owning these dividend stocks could be a simple way to make money over the long term.

Via The Motley Fool

Topics Intellectual Property

Abbott Laboratories (NYSE:ABT) Clears All Quality Investing Hurdles ↗

August 26, 2026

Via Chartmill

Abbott Laboratories (NYSE:ABT): A Strong Candidate for Quality Investors ↗

July 30, 2026

Via Chartmill

If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio ↗

September 02, 2026

The Schwab US Dividend Equity ETF is a safe all-weather investment.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Just Starting Out With $5,000? 3 Magnificent ETFs to Buy in 2026. ↗

August 31, 2026

These 3 ETFs would give you a strong long-term portfolio to build from.

Via The Motley Fool

Topics ETFs

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy. ↗

August 26, 2026

His AbbVie purchase was a big move into a high-yielding dividend stock.

Via The Motley Fool

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. ↗

August 24, 2026

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Via The Motley Fool

Topics Intellectual Property

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson? ↗

August 23, 2026

These two high-quality dividend payers have had very different fortunes recently.

Via The Motley Fool

Topics Lawsuit

Recent Report Shows That Rep. Rick Allen Sold Up to $50K Worth of Abbott Laboratories Stock ↗

August 19, 2026

An official report on August 18, 2026 reveals Representative Rick Allen's recent sale of Abbott Laboratories (NYSE:ABT) stock, valued between $15,001 and $50,000. The transaction took place on July 14,...

Via Benzinga

If You Invest $100 a Month in SCHD, Here's the Passive Income It Could Deliver in 20 Years ↗

August 17, 2026

This top dividend ETF is still a reliable long-term income investment.

Via The Motley Fool

Topics ETFs Retirement Stocks

Recent Report Shows That Rep. Richard Dean Dr McCormick Sold Up to $375K Worth of Abbott Laboratories Stock ↗

August 17, 2026

Records from August 14, 2026 indicate that Representative Richard Dean Dr McCormick of Georgia made a sale of Abbott Laboratories (NYSE:ABT), valued between $25,025 and $375,000, with the transaction...

Via Benzinga

The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. ↗

August 16, 2026

Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Recession-Proofing Your Portfolio Before the Storm Hits ↗

August 13, 2026

Whether a recession is coming in 2026 or five years from now, the best investors are always figuring out how to prepare.

Via The Motley Fool

Topics Economy

The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession ↗

August 11, 2026

These stocks can help you withstand (almost) any storm.

Via The Motley Fool

Topics Economy

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? ↗

August 11, 2026

The pharmaceutical company hopes that another big-time acquisition will pay off.

Via The Motley Fool

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 07, 2026

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Via The Motley Fool

Solventum Nears Inflection Point As It Begins to Unlock Value ↗

August 07, 2026

Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers.

Via MarketBeat

Topics Initial Public Offering

This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now ↗

August 05, 2026

There is no end in sight for the drugmaker's dividend growth streak.

Via The Motley Fool

Topics Intellectual Property

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 02, 2026

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.

Via The Motley Fool

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 31, 2026

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Via The Motley Fool

3 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

July 29, 2026

These companies' recent headwinds shouldn't lead to decreased payouts.

Via The Motley Fool

Topics Intellectual Property

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗

July 29, 2026

AbbVie still looks like a compelling buy at its all-time high.

Via The Motley Fool

Topics Intellectual Property

Why Wall Street Can't Get Enough of This Dividend King ↗

July 25, 2026

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Via The Motley Fool

Topics Intellectual Property

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow ↗

July 21, 2026

It looks like a great buy-and-hold option.

Via The Motley Fool

Topics Intellectual Property

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗

July 19, 2026

There's no need to panic.

Via The Motley Fool

My 2 Favorite Dividend Kings to Buy Right Now ↗

July 19, 2026

They can help stabilize your portfolio in these otherwise volatile times.

Via The Motley Fool

Topics Intellectual Property

This Dividend ETF Yields 3.2% and Is Beating the Nasdaq-100 This Year ↗

July 18, 2026

A portfolio of dividend payers with decade-long track records is outrunning the AI-heavy growth indexes.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results ↗

July 17, 2026

Abbott Laboratories (NYSE:ABT) reported strong Q2 results, raising its full-year earnings outlook. Analysts have a positive outlook on ABT stock.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.